| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 09/07/2004 | US6787355 Multipotent neural stem cells from peripheral tissues and uses thereof |
| 09/07/2004 | US6787342 Paste formulations |
| 09/07/2004 | US6787319 Nucleotide sequences coding polypeptide for use in the treatment of alzheimer's disease |
| 09/02/2004 | WO2004074290A1 Substituted amino heterocycles as vr-1 antagonists for treating pain |
| 09/02/2004 | WO2004074286A1 Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
| 09/02/2004 | WO2004074281A1 Benzofuran oxyethylamines serving as antidepressant drugs and anxiolytic drugs |
| 09/02/2004 | WO2004074277A1 N-aryl- or n-heteroarylpiperazine derivative and medicine containing the same |
| 09/02/2004 | WO2004074259A1 Aryl acid pyrimidinyl methyl amides, pyridazinyl methyl amides and related compounds |
| 09/02/2004 | WO2004074243A2 Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands |
| 09/02/2004 | WO2004074232A1 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases |
| 09/02/2004 | WO2004073741A1 Remedy for spinal injury containing interleukin-6 antagonist |
| 09/02/2004 | WO2004073723A1 Medical drug containing fine particle of noble metal |
| 09/02/2004 | WO2004073722A1 Superoxide anion decomposing agent |
| 09/02/2004 | WO2004073712A1 Pharmaceutical combinations comprising a nos inhibitor and an nmda receptor antagonist |
| 09/02/2004 | WO2004073705A1 1-phenyl-2- monoalkyl carboxylic acid derivatives for the treatment of neurodegenerative diseases |
| 09/02/2004 | WO2004073698A1 Therapeutic use of acyl glycerols and the nitrogen- and sulphur-containing analogues therof |
| 09/02/2004 | WO2004073653A2 Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same |
| 09/02/2004 | WO2004073595A2 Novel purine derivatives, preparation method thereof, application of same as medicaments, pharmaceutical compositions and novel use |
| 09/02/2004 | WO2004073588A2 Diagnostics and therapeutics for diseases associated with g protein coupled receptor r35 (r35) |
| 09/02/2004 | WO2004073583A2 Use of antimuscarinic drugs for preventing the onset of epilepsy |
| 09/02/2004 | WO2004060361A3 Combination of reboxetine and a cyclooxygenase-2 inhibitor |
| 09/02/2004 | WO2004056324A3 Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists |
| 09/02/2004 | WO2004048978A3 Diagnostics and therapeutics for diseases associated with bile acid g-protein-coupled receptor 37 (bg37) |
| 09/02/2004 | WO2004020665A3 Diagnostic and therapeutic use of foap-13 polynucleotides and polypeptides for neurodegenerative diseases |
| 09/02/2004 | WO2004002421A3 Method for the treatment of multiple sclerosis |
| 09/02/2004 | WO2003099786A3 Aromatic sulfones and their medical use |
| 09/02/2004 | WO2003085131A3 Diagnostic and therapeutic use of vault polynucleotides and proteins for neurodegenerative diseases |
| 09/02/2004 | WO2003049698A8 Substituted hydrazones as inhibitors of cyclooxygenase-2 |
| 09/02/2004 | US20040171881 N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives |
| 09/02/2004 | US20040171851 Process for the preparation of 5-carboxyphthalide |
| 09/02/2004 | US20040171848 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 09/02/2004 | US20040171832 Novel sulfonate substituted pyrazol pyridine derivatives |
| 09/02/2004 | US20040171830 Carboline derivatives as pdev inhibitors |
| 09/02/2004 | US20040171816 Humanized antibodies that recognize beta amyloid peptide |
| 09/02/2004 | US20040171815 treatment of diseases associated with amyloid deposits in the brain (pre-clinical Alzheimer's disease or Down's syndrome); genetic engineering |
| 09/02/2004 | US20040171804 for drug screening cancer, osteoporosis, obesity, Alzheimer's disease drugs; genetic engineering; kits |
| 09/02/2004 | US20040171802 Haemophilus influenzae antigens and corresponding dna fragments |
| 09/02/2004 | US20040171696 Formulations containing 2-(2-dimethylaminoethoxy)-2-phenyl-1,7,7-trimethylbicyclo[2.2.1]heptane (known as deramciclane); Parkinson's disease, Korsakoff syndrome, Huntington's disease |
| 09/02/2004 | US20040171690 Use of protein essential aminoacids to treat amenorrhea and related disorders |
| 09/02/2004 | US20040171685 Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia |
| 09/02/2004 | US20040171679 Carbamate compounds for use in preventing or treating neurodegenerative disorders |
| 09/02/2004 | US20040171671 Cyclic ester of 3-hydroxybutyric acid; increasing cardiac efficiency, alternative glucose energy source, free radical scavenging |
| 09/02/2004 | US20040171667 Antidepressant cycloalkylamine derivatives of heterocycle-fused benzodioxans |
| 09/02/2004 | US20040171666 Rapid, thorough absorption; eliminates gastrointestional disorder and reduces central nervous system stimulation side effects; low cost |
| 09/02/2004 | US20040171658 Blood coagulation factor Xa inhibition; such as 2-O-(3'-amidinobenzyl)-5-O-(3''-amidinophenyl)-1,4:3,6-dianhydrosorbitol |
| 09/02/2004 | US20040171645 Treating extrapyramidal movement disorder adverse effects of antiparkinson's drugs |
| 09/02/2004 | US20040171643 Acylaminothiazole derivatives, their preparation and therapeutic use |
| 09/02/2004 | US20040171639 Heterocyclic ureas, their preparation and their use as vanilloid receptor antagonists |
| 09/02/2004 | US20040171633 (1, 8) naphthyridines as gaba ligands, their pharmaceutical compositions and uses |
| 09/02/2004 | US20040171624 Pharmaceutical composition for treating mood disorders |
| 09/02/2004 | US20040171619 Novel 2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient |
| 09/02/2004 | US20040171618 Compounds as PDE IV and TNF-inhibitors |
| 09/02/2004 | US20040171617 treatment for disorders and diseases, such as chronic inflammation, tissue breakdown and cancer |
| 09/02/2004 | US20040171615 Substituted 1-aryl-but-3-enylamine and 1-aryl-but-2-enylamine compounds |
| 09/02/2004 | US20040171614 Novel gamma secretase inhibitors |
| 09/02/2004 | US20040171612 Novel compounds with analgesic effect |
| 09/02/2004 | US20040171610 treating a patient for sleep disorders |
| 09/02/2004 | US20040171607 Chemical compounds |
| 09/02/2004 | US20040171606 antagonism/inhibition, of the D3 receptor; substance abuse. |
| 09/02/2004 | US20040171605 Benzoxazepines derivatives and their use as ampa receptor stimulators |
| 09/02/2004 | US20040171592 reduced gastric effects; salicylic acid derivatives |
| 09/02/2004 | US20040171581 Polysaccharidic esters of retinoic acid |
| 09/02/2004 | US20040171568 oligonucleotide at least 29 nucleotides in length, wherein the anti-HIV activity of said oligonucleotide occurs principally by a non-sequence complementary mode of action |
| 09/02/2004 | US20040171558 sulfamate; represented by topiramate; retinal embolism, ischemic optic neuropathy, macular degeneration, retinitis pigmentosa or Leber's disease |
| 09/02/2004 | US20040171555 inhibitors of dipeptidyl peptidase; treatment of impaired glucose tolerance, glucosuria, hyperlipidaemia, metabolic acidoses, diabetes mellitus, diabetic neuropathy and nephropathy and of sequelae of diabetes mellitus in mammals |
| 09/02/2004 | US20040171553 Peptides fragments of colostrinin and their use |
| 09/02/2004 | US20040171530 Polypeptides containing cysteine and tryptophan |
| 09/02/2004 | US20040171123 fusion protein of an antibody that binds to human epidermal growth factor receptor-2 (HER2) and albumin with long shelf-life; stabilizing therapeutic proteins such as antibodies by conjugating them to albumin |
| 09/02/2004 | US20040171117 Anti-RANK ligand monoclonal antibodies useful in treatment of RANK ligand mediated disorders |
| 09/02/2004 | US20040171080 Method of assaying for agonists or antagonist of dynorphin a binding to the mas receptor |
| 09/02/2004 | US20040171012 Nucleic acid-associated proteins |
| 09/02/2004 | US20040170999 Nuclear hormone receptor ligand binding domain |
| 09/02/2004 | US20040170997 used in drug screening for preventing or treating diseases associated with abnormalities in intracellular signal transduction; genetic engineering |
| 09/02/2004 | US20040170995 for drug screening in vitro for mitogen-activated protein kinase-activated protein kinase-2 modulators using expression libraries; genetic engineering; kits |
| 09/02/2004 | US20040170969 GRF2 binding proteins and applications thereof |
| 09/02/2004 | US20040170959 Methods for identifying antiviral oligonucleotides |
| 09/02/2004 | US20040170704 Process for the manufacture of a herbal composition |
| 09/02/2004 | US20040170701 Pharmaceutical composition comprising copper, salicylic acid, vitamin c and zinc for use in treatment of different diseases such as bacterial or viral infection |
| 09/02/2004 | US20040170684 For therapy of incontinence |
| 09/02/2004 | US20040170680 For orally administering oxycodone to provide analgesic therapy beyond its relatively short half-life over an extended period of time, and having a duration of pain relief of at least 24-hours |
| 09/02/2004 | US20040170673 Adhesive emulsion for medical purposes made from ethylene-vinyl acetate copolymers and adhesive resins |
| 09/02/2004 | US20040170654 bolus injection to skin; increased systemic absorption produced compared to absorption produced on delivering the agonist subcutaneously by bolus injection; particularly applicable to tricyclic nitrogen-containing compounds, e.g., R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinoline-2(1H)-thione |
| 09/02/2004 | US20040170641 Prevention and treatment of amyloidogenic disease |
| 09/02/2004 | US20040170635 administering an inhibitor of the CD2/LFA-3 interaction, in combination with narrow band UVB radiation; especially for treating psoriasis |
| 09/02/2004 | US20040170627 Antagonists of Myelin-associated Glycoprotein and their use in the treatment and/or prevention of Neurological diseases |
| 09/02/2004 | US20040170618 antagonists bind to a recognized target (e.g., a receptor); the enzyme component of the chimera then degrades the target resulting in a reduction of activity of the target and release of the chimeric molecule, which is then free to attack and degrade another target molecule. |
| 09/02/2004 | US20040170608 Use of a lentiviral vector in the treatment of pain |
| 09/02/2004 | US20040170573 Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route |
| 09/02/2004 | US20040170569 Dosage forms that rapidly produces peak plasma concentrations; heating a thin layer of the drug on a solid support to form a vapor; and passing air through the heated vapor to produce aerosol particles having less than 10% drug degradation products |
| 09/02/2004 | CA2518313A1 Medicament comprising noble metal fineparticles |
| 09/02/2004 | CA2518311A1 Superoxide anion scavenger |
| 09/02/2004 | CA2516945A1 Therapeutic agent for spinal cord injury comprising interleukin-6 antagonist |
| 09/02/2004 | CA2516679A1 The use of antimuscarinic drugs |
| 09/02/2004 | CA2516454A1 Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same |
| 09/02/2004 | CA2515610A1 Novel purine derivatives, preparation method thereof, application of same as medicaments, pharmaceutical compositions and novel use |
| 09/02/2004 | CA2515571A1 Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
| 09/02/2004 | CA2515570A1 Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands |
| 09/02/2004 | CA2515567A1 Pharmaceutical combinations comprising a nos inhibitor and an nmda receptor antagonist |
| 09/02/2004 | CA2514908A1 Substituted amino heterocycles as vr-1 antagonists for treating pain |
| 09/02/2004 | CA2508731A1 Aryl acid pyrimidinyl methyl amides, pyridazinyl methyl amides and related compounds |